A Prospective, Randomized, Open Label, Phase III, Multicentric Clinical Trial To Compare The Efficacy And Safety Of Monoclonal Anti Rho (D) Immunoglobulin With Polyclonal Anti Rho (D) Immunoglobulin In Prevention of Hemolytic Disease Of Newborn.

Trial Profile

A Prospective, Randomized, Open Label, Phase III, Multicentric Clinical Trial To Compare The Efficacy And Safety Of Monoclonal Anti Rho (D) Immunoglobulin With Polyclonal Anti Rho (D) Immunoglobulin In Prevention of Hemolytic Disease Of Newborn.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Anti-D Rh0 immunoglobulin
  • Indications Haemolytic disease of newborn
  • Focus Therapeutic Use
  • Sponsors Bharat Serums and Vaccines
  • Most Recent Events

    • 13 Mar 2017 Status changed from not yet recruiting to completed.
    • 02 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top